Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1
Wolfram syndrome 1 is a very rare monogenic disease resulting in a complex of disorders including diabetes mellitus. Up to now, insulin has been used to treat these patients. Some of the monogenic forms of diabetes respond preferentially to sulphonylurea preparations. The aim of the current study wa...
Saved in:
Main Authors: | Tuuli Sedman, Kertu Rünkorg, Maarja Krass, Hendrik Luuk, Mario Plaas, Eero Vasar, Vallo Volke |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2016/9239530 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
by: Xuan Du, et al.
Published: (2018-01-01) -
A Rare Case of Wolfram Syndrome Presenting With Tuberculous Meningitis: A Case Report
by: Nabiha Khan, et al.
Published: (2025-01-01) -
Wolfram Syndrome: A Case Report and Review of Clinical Manifestations, Genetics Pathophysiology, and Potential Therapies
by: N. B. Toppings, et al.
Published: (2018-01-01) -
The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
by: Jie Wang, et al.
Published: (2019-01-01) -
Identification of a pathogenic founder variant in the WFS1 gene that causes Wolfram syndrome in the Druze population
by: Inbal Halabi, et al.
Published: (2025-01-01)